Clinical Trial Results:
Gemtuzumab Ozogamicin (GO) monotherapy versus standard supportive care for previously untreated AML in elderly patients who are not eligible for intensive chemotherapy: a randomized phase II/III trial (AML-19)of the EORTC-LG and GIMEMA-ALWP
Summary
|
|
EudraCT number |
2004-004356-39 |
Trial protocol |
IT |
Global completion date |
06 May 2013
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
24 Mar 2017
|
First version publication date |
24 Mar 2017
|
Other versions |
|
Summary report(s) |
06031_ShortReportAuthorities_20150714.pdf |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.